Since its establishment in Tianjin, China in 2009, it has experienced tremendous growth with now more than 600 employees, one approved vaccine for Ebola virus disease (Ad5-EBOV) and 16 vaccine candidates in the product pipeline. It has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. 

It is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates.

CanSino is a well-known company in the pharmaceutical industry. The production process of this project has very high requirements for steam quality (steam dryness), and pressure/temperature stability under load changes. Year after year, KLD Steam Generators perform as required, high quality and stable steam.